Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy

Expert Review of Endocrinology and Metabolism

Volumn 6, Issue 1, 2011, Pages 21-30

  Mateo, Maria Gracia ^a   Gutiérrez, Maria Del Mar ^a   Domingo, Pere ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

excess abdominal fat; growth hormone releasing factor analogue; HIV 1 infection; lipodystrophy; tesamorelin

Indexed keywords

GLUCOSE; INSULIN; PLACEBO; RITONAVIR; SIMVASTATIN; TESAMORELIN; TRIACYLGLYCEROL;

ABDOMINAL FAT; ARTHRALGIA; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CARPAL TUNNEL SYNDROME; DRUG ABSORPTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXCESS ABDOMINAL FAT; GLUCOSE BLOOD LEVEL; HEART RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INSULIN BLOOD LEVEL; MULTICENTER STUDY; MYALGIA; NONHUMAN; OBESITY; PARESTHESIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF CONCEPT; SIDE EFFECT; SUBCUTANEOUS FAT;

EID: 78650430109     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.10.83     Document Type: Article

References (33)

1. Villarroya F, Domingo P, Giralt M. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol. Sci. 26, 88-93 (2005).
2. Mallon PW, Miller J, Cooper DA et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 17(7), 971-979 (2003).
3. Dube MP, Parker RA, Tebas P et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 19, 1807-1818 (2005).
4. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349, 1993-2003 (2003).
5. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 352, 48-62 (2005).
6. Milinkovic A, Vidal S, Bianchi L et al. Comparative assessment of objective methods for the measurement of body fat. Antivir. Ther. 8, L63 (2003).
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
8. Guaraldi G, Stentarelli C, Zona S et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in HIV infected subjects. Atherosclerosis 208, 222-227 (2010).
9. Guaraldi G, Zona S, Orlando G et al. Visceral fat but not general adiposy is a predictor of cardiovascular disease in HIV-infected males. Presented at: 17th Conference on Retroviruses and Opportunistic Infection. San Francisco, CA, USA, 16-19 February 2010.
10. Snel Y, Brummer R-JM, Doerga ME et al. Adipose tissue assessed by magnetic resonance imaging in growth hormone deficient adults: the effect of growth hormone replacement and a comparison with control subject. Am. J. Clin. Nutr. 61, 1290-1294 (1995).
11. De Boer H, Blok GJ, Voerman B et al. Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men. Int. J. Obes. Relat. Metab. Disord. 20, 580-587 (1996).
12. Rietschel P, Hadigan C, Corcoran C et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J. Clin. Endocrinol. Metab. 86, 504-510 (2001).
13. Koutkia P, Meininger G, Canavan B et al. Metabolic regulation of growth hormone by free fatty acids, somatostatine, and ghrelin in HIV-lipodystrophy. Am. J. Physiol. Endocrinol. Metab. 286, E296-E303 (2004).
14. Torres RA, Unger KW, Cadman JA et al. Recombinant human growth hormone improves truncal adiposity and 'buffalo humps' in HIV-positive patients on HAART [letter]. AIDS 13, 2479-2481 (1999).
15. Wanke C, Gerrior J, Kantaros J et al. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13, 2099-2103 (1999).
16. Lo JC, Mulligan K, Noor MA et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J. Clin. Endocrinol. Metab. 86, 3480-3487 (2001).
17. Engelson ES, Glesby MJ, Mendez D et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J. Acquir. Immune Defic. Syndr. 30, 379-391 (2002).
18. Schwarz JM, Mulligan K, Lee J et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J. Clin. Endocrinol. Metab. 87, 942 (2002).
19. Chan JM, Stampfer MJ, Giovannucci E et al. Plasma IGF-1 and prostate cancer risk: a prospective study. Science 279, 563-566 (1998).
20. Hankinson SE, Willett WC, Colditz GA et al. Circulating concentrations of IGF-1 and the risk of breast cancer. Lancet 351, 1393-1396 (1998).
21. Ma J, Pollak MN, Giovannuci E et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl Cancer Inst. 91(7), 620-625 (1999).
22. Koutkia P, Canavan B, Breu J et al. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized, controlled trial. JAMA 292, 210-218 (2004).
23. Lönn L, Johannsson G, SjÖstrÖm L et al. Body composition and tissue distribution in growth hormone deficient adults before and after growth hormone treatment. Obes. Res. 4, 45-54 (1996).
24. Falutz J, Allas S, Kotler D et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 19, 1279-1287 (2005).
25. Falutz J, Allas S, Blot K et al. Metabolic effects of a growth hormone releasing factor in patients with HIV. N. Engl. J. Med. 357, 2359-2370 (2007).
26. Falutz J, Allas S, Mamputu J-C et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 22, 1719-1728 (2008).
27. Falutz J, Potvin D, Mamputu J-C et al. Effects of tesamorelin, a growth hormone releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized, placebo-controlled, trial with a safety extension. J. Acquir. Immune Defic. Syndr. 53(3), 311-322 (2010).
28. Frohman LA, Downs TR, Williams TC et al. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2- terminus. J. Clin. Invest. 78, 906-991 (1986).
29. Larocque A, Vaillancourt C, Abribat T et al. Anchoring rigid hydrophobic chains to stabilize growth hormone-releasing factor. Theratechnologies Inc., St. Laurent and University of Montreal, Montreal, Quebec, Canada (2001).
30. Michaud S-E, Abolfathi Z. Pharmacokinetic/pharmacodynamic evaluation of tesamorelin (TH9507), a growth hormone-releasing factor (GRF) analog, administered subcutaneously once daily for 14 consecutive days in healthy and HIV positive populations. Presented at: Endocrine Society's 91st Annual Meeting. Washington, DC, USA, 10-13 June 2009.
31. Falutz J, Mamputu J-C. Metabolic effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in hiv-infected patients with excess abdominal fat over a period of 52 weeks. a pooled analysis of 2 multicenter, double- blind, placebo-controlled Phase 3 trials with 816 randomized patients. Presented at: 12th European AIDS Conference. Cologne, Germany, 11-14 November 2009.
32. Ferdinandi ES, Brazeau P, High K et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin. Pharmacol. Toxicol. 100(1), 49-58 (2007).
33. Vincent G, Teng S. Impact of tesamorelin (TH9507), a stabilized growth hormone-releasing factor (GRF) analogue, on the pharmacokinetics of simvastatin and ritonavir in healthy volunteers. Presented at: 18th Annual Canadian Conference on HIV/AIDS Research. Vancouver, BC, Canada, 23-26 April 2009.